Welcome to today's Medical News Today News Alert containing today's medical news headlines for your chosen categories. You will only receive these alerts when new news is available for your chosen categories.
To unsubscribe from our news alerts, or to alter any of your subscription details (name,e-mail address etc) please see
http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y .
----------------------------------------------
** BREAST CANCER News **
Advalytix Announces Study Of Single Circulating Tumor Cells With The M. D. Anderson Cancer Center
http://www.medicalnewstoday.com/articles/121256.php
The Advalytix product team of Olympus is initiating a collaborative study with The University of Texas M. D. Anderson Cancer Center to characterize circulating tumor cells in breast cancer patients.
Study suggests more Asian American women may need to be tested for BRCA mutations
http://www.medicalnewstoday.com/articles/121230.php
In this New Digest:<ul><li> Summary of a study published online September 8, 2008 in the<i> Journal of Clinical Oncology</i>, showing that computer models commonly used to decide who might benefit most from genetic testing under predicted the number of Asian-American women with BRCA1 or BRCA2 mutations.
----------------------------------------------
** CANCER / ONCOLOGY News **
ESMO 2008 - GSK To Present Encouraging New Data Supporting Late Stage Development Programme
http://www.medicalnewstoday.com/articles/121324.php
At the 33rd meeting of the European Society for Medical Oncology (ESMO) Stockholm, Sweden, GlaxoSmithKline (GSK) Oncology will present exciting new data for Tyverb® (lapatinib) and pazopanib.
Researchers Link Defects In Mitochondria To Abnormal Nuclear Genome Packaging In Cancer Cells
http://www.medicalnewstoday.com/articles/121262.php
New research by Roswell Park Cancer Institute (RPCI) scientists may help explain how cancer develops. In a study published in the journal <i>Cancer Biology and Therapy</i>*, authors Keshav K.
Argos Therapeutics Initiates Phase 2 Trial In Renal Cell Carcinoma For Its Arcelis™ Personalized Immunotherapy Platform
http://www.medicalnewstoday.com/articles/121258.php
Argos Therapeutics announced the initiation of a Phase 2a trial of its AGS-003 therapy, in combination with sunitinib, for the treatment of newly diagnosed advanced renal cell carcinoma (RCC).
Advalytix Announces Study Of Single Circulating Tumor Cells With The M. D. Anderson Cancer Center
http://www.medicalnewstoday.com/articles/121256.php
The Advalytix product team of Olympus is initiating a collaborative study with The University of Texas M. D. Anderson Cancer Center to characterize circulating tumor cells in breast cancer patients.
Merck Serono Submits New License Application For Erbitux In 1st-Line Non-Small Cell Lung Cancer In Europe
http://www.medicalnewstoday.com/articles/121239.php
Merck Serono announced that it has submitted an application to the European Medicines Agency (EMEA) to license Erbitux (cetuximab) for the 1st-line treatment of epidermal growth factor receptor (EGFR) expressing, advanced or metastatic non-small cell lung cancer (NSCLC).
Researchers Develop Nano-Sized 'Cargo Ships' To Target And Destroy Tumors
http://www.medicalnewstoday.com/articles/121237.php
Scientists have developed nanometer-sized 'cargo ships' that can sail throughout the body via the bloodstream without immediate detection from the body's immune radar system and ferry their cargo of anti-cancer drugs and markers into tumors that might otherwise go untreated or undetected.
Study Published In New England Journal Of Medicine Shows ERBITUX® Improved Survival In First-Line Recurrent And/Or Metastatic Head And Neck Cancer
http://www.medicalnewstoday.com/articles/121231.php
ImClone Systems Incorporated (NASDAQ: IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) announced the publication of results from a Phase 3 trial in the New England Journal of Medicine of ERBITUX® (cetuximab) plus platinum-based chemotherapy in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).
Amgen To Present Important Clinical Trial Data At Two Key Congresses
http://www.medicalnewstoday.com/articles/121224.php
Amgen (NASDAQ:AMGN) announced it will present new data from osteoporosis studies of its investigational therapy, denosumab, at the 2008 American Society of Bone and Mineral Research (ASBMR) Annual Meeting that will be held in Montreal, Sept.
Roche To Present Data Showing Progress In Treating Lung, Gastric And Brain Cancers At ESMO
http://www.medicalnewstoday.com/articles/121222.php
More than 100 Roche abstracts have been accepted for the biggest cancer congress in Europe, the European Society for Medical Oncology (ESMO), which opens in Stockholm on Friday (12th September).
Untapped Potential Of Antidepressants For Cancer
http://www.medicalnewstoday.com/articles/121211.php
A comprehensive review of current scientific literature, published in the peer-reviewed journal ecancer, has suggested that antidepressants can help the human body fight cancer by boosting its own immune response, amongst other mechanisms.
Long-Term Phase I And Phase I/II Trial Data Continue To Show Striking Improvement In Survival Of Brain Cancer Patients Who Receive DCVax(R)-Brain
http://www.medicalnewstoday.com/articles/121198.php
Northwest Biotherapeutics, Inc. (OTC Bulletin Board: NWBO; AIM: NWBT and NWBS) ("NWBT" or the "Company") announced the most recent long-term follow-up data, through June 15, 2008, from its prior Phase I and Phase I/II clinical trials with DCVax(R)-Brain, which began in 2000 and 2003, for patients with Glioblastoma multiforme, the most lethal type of brain cancer.
CuraGen Completes Enrollment In Phase II Trial Of CR011-vcMMAE In Metastatic Melanoma
http://www.medicalnewstoday.com/articles/121196.php
CuraGen Corporation (Nasdaq: CRGN), a clinical-stage biopharmaceutical company focused on oncology, today announced that it has completed the enrollment of patients into its Phase II trial evaluating CR011-vcMMAE for the treatment of advanced melanoma.
Erbitux First Treatment In 30 Years To Significantly Prolong Survival In 1st-Line Recurrent And/Or Metastatic Head And Neck Cancer
http://www.medicalnewstoday.com/articles/121167.php
Data published in the <i>New England Journal of Medicine</i> show that Erbitux® (cetuximab) significantly increases overall survival when added to standard chemotherapy in the 1st-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).
Van Andel Institute Researchers Are First To Associate Unique DNA Changes With Several Types Of Renal Cell Carcinoma
http://www.medicalnewstoday.com/articles/121164.php
Van Andel Institute (VAI) researchers have identified unique DNA changes in each of several types of renal cell carcinoma (RCC), the most common form of kidney cancer in adults. These findings could aid in the diagnosis of these cancers since the many types of RCC are currently identified only by their appearance.
Aptium Oncology Launches Multi-Institutional GI Consortium To Advance Research And Treatment Protocols
http://www.medicalnewstoday.com/articles/121134.php
Aptium Oncology, Inc. announced the launch of Aptium Oncology GI Cancer Consortium (AGICC), consisting of eight member institutions. Each AGICC institution has demonstrated expertise in the multidisciplinary and translational approach to gastrointestinal (GI) malignancies.
----------------------------------------------
** CERVICAL CANCER / HPV VACCINE News **
No news for this category today.
----------------------------------------------
** COLORECTAL CANCER News **
No news for this category today.
----------------------------------------------
** LUNG CANCER News **
Important Updates To The NCCN Drugs & Biologics Compendium™ Non-Small Cell Lung Cancer
http://www.medicalnewstoday.com/articles/121252.php
The National Comprehensive Cancer Network (NCCN) announces important updates to the NCCN Drugs & Biologics Compendium™ Non-Small Cell Lung Cancer. The following changes relate to use in the treatment of Non-Small Cell Lung Cancer and are as follows: - Cetuximab (Erbitux, Bristol-Myers Squibb/ImClone Systems Incorporated) - First-line therapy for recurrence or metastasis in combination with vinorelbine and cisplatin for performance status 0-2 patients at least 18 years of age with NSCLC IIIB (pleural effusion)/IV, EGFR expression by immunohistochemistry (at least 1 positive tumor cell), no known brain metastases, and no prior chemotherapy or anti-EGFR therapy.
Merck Serono Submits New License Application For Erbitux In 1st-Line Non-Small Cell Lung Cancer In Europe
http://www.medicalnewstoday.com/articles/121239.php
Merck Serono announced that it has submitted an application to the European Medicines Agency (EMEA) to license Erbitux (cetuximab) for the 1st-line treatment of epidermal growth factor receptor (EGFR) expressing, advanced or metastatic non-small cell lung cancer (NSCLC).
----------------------------------------------
** LYMPHOMA / LEUKEMIA News **
No news for this category today.
----------------------------------------------
** PROSTATE / PROSTATE CANCER News **
Leading British Artists Unite Against Prostate Cancer
http://www.medicalnewstoday.com/articles/121214.php
More than 40 of Britain's leading male artists have united in the fight against prostate cancer, donating their works for the <a href="http://www.menonlyart.co.uk/men_only.html" target="_blank" rel="nofollow">Everyman Men Only exhibition</a> to be held at Liberty in London from 8 to 11 September.
-------------------------------------------------------------
You are receiving this news alert e-mail because you subscribed via an online form on our web site. If you wish to unsubscribe, please visit
http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y .
No comments:
Post a Comment